Cylene: Home



		Our proprietary Ribosomal RNA Biogenesis Inhibitor Technology (RABIT™) is generating a diverse array of small molecule therapeutics for the treatment of various types of cancers. View PRODUCTS in the PIPELINE More on our DISCOVERY ENGINE March 14, 2008 Cylene Pharmaceuticals Promotes Claire S. Padgett to Vice President of Clinical Operations January 28, 2008 Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology CX-3543 is a first-in-class Ribosomal RNA Biogenesis Inhibitor that induces apoptotic cell death in tumor cells; the compound is in early Phase II clinical trials in patients with chronic lymphocytic leukemia, and is in late Phase I trials in patients with solid tumors. Daniel Von Hoff, M.D., F.A.C.P. and John Lim, Pharm.D. guide clinical trials.

© 2008 Cylene Pharmaceuticals | Terms of Use | Privacy Policy

CONTACT

SITE MAP


Leadership
Frequently Asked Questions
Terms and Definitions


Quarfloxin: Lead Product Ribosomal RNA Biogenesis Inhibitor (RBI)
CX-4945: Oral CK2 Inhibitors
CX-3800 Series of Pol I Complex Inhibitors
Pol I Inhibitor (CX-3773)
Psorospermin/CX-1338: Unconventional Transcription Inhibitor Series


Media Clips